Recorlev-driven commercial momentum funds XP-8121's Phase 3 entry into hypothyroidism, contingent on sustaining revenue growth

Xeris is a commercial-stage biopharmaceutical company with an approved treatment for Cushing's syndrome that is funding early-stage development of an unapproved drug candidate for hypothyroidism.

Recorlev, Xeris's approved treatment for endogenous Cushing's syndrome, generated $106.5M in the first half of 2026, up 87% year-over-year, anchoring a profitable commercial base. That revenue engine is funding Phase 3 initiation of XP-8121 in hypothyroidism, a substantially larger addressable market. Whether XP-8121 can demonstrate registrational efficacy in a field dominated by established generic levothyroxine determines the pipeline's long-term value creation.